Reelin expression in Creutzfeldt-Jakob disease and experimental models of transmissible spongiform encephalopathies

dc.contributor.authorMata Rodríguez, Agata
dc.contributor.authorUrrea Zazurca, Laura
dc.contributor.authorVilches Saez, Silvia
dc.contributor.authorLlorens Torres, Franc
dc.contributor.authorThüne, Katrin
dc.contributor.authorEspinosa, Juan Carlos
dc.contributor.authorAndréoletti, Olivier
dc.contributor.authorSevillano, Alejandro M.
dc.contributor.authorTorres, Juan María
dc.contributor.authorRodríguez Requena, Jesús
dc.contributor.authorZerr, Inga
dc.contributor.authorFerrer, Isidro (Ferrer Abizanda)
dc.contributor.authorGavín Marín, Rosalina
dc.contributor.authorRío Fernández, José Antonio del
dc.date.accessioned2019-10-07T15:42:42Z
dc.date.available2019-10-07T15:42:42Z
dc.date.issued2017-10-01
dc.date.updated2019-10-07T15:42:43Z
dc.description.abstractReelin is an extracellular glycoprotein involved in key cellular processes in developing and adult nervous system, including regulation of neuronal migration, synapse formation, and plasticity. Most of these roles are mediated by the intracellular phosphorylation of disabled-1 (Dab1), an intracellular adaptor molecule, in turn mediated by binding Reelin to its receptors. Altered expression and glycosylation patterns of Reelin in cerebrospinal and cortical extracts have been reported in Alzheimer's disease. However, putative changes in Reelin are not described in natural prionopathies or experimental models of prion infection or toxicity. With this is mind, in the present study, we determined that Reelin protein and mRNA levels increased in CJD human samples and in mouse models of human prion disease in contrast to murine models of prion infection. However, changes in Reelin expression appeared only at late terminal stages of the disease, which prevent their use as an efficient diagnostic biomarker. In addition, increased Reelin in CJD and in in vitro models does not correlate with Dab1 phosphorylation, indicating failure in its intracellular signaling. Overall, these findings widen our understanding of the putative changes of Reelin in neurodegeneration.
dc.format.extent14 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec666918
dc.identifier.issn0893-7648
dc.identifier.pmid27726110
dc.identifier.urihttps://hdl.handle.net/2445/141772
dc.language.isoeng
dc.publisherHumana Press.
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1007/s12035-016-0177-8
dc.relation.ispartofMolecular Neurobiology, 2017, vol. 54, num. 8, p. 6412-6425
dc.relation.urihttps://doi.org/10.1007/s12035-016-0177-8
dc.rights(c) Humana Press., 2017
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject.classificationMetabolisme
dc.subject.classificationMalaltia de Creutzfeldt-Jakob
dc.subject.classificationMatriu extracel·lular
dc.subject.classificationTeixit nerviós
dc.subject.classificationMalalties per prions
dc.subject.otherMetabolism
dc.subject.otherCreutzfeldt-Jakob disease
dc.subject.otherExtracellular matrix
dc.subject.otherNerve tissue
dc.subject.otherPrion diseases
dc.titleReelin expression in Creutzfeldt-Jakob disease and experimental models of transmissible spongiform encephalopathies
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
666918.pdf
Mida:
3.8 MB
Format:
Adobe Portable Document Format